Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Maryland
  • Gaithersburg


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia
    NCT03359785
    Condition:   Schizophrenia
    Interventions:   Drug: TAK-831 500 mg;   Drug: TAK-831 50 mg;   Drug: Matching Placebo
    Sponsor:   Takeda
    Recruiting
  • The HOPE Study: Characterizing Patients With Hepatitis B and C
    NCT02995252
    Conditions:   Hepatitis B, Chronic;   Hepatitis C
    Interventions:   Other: Blood draws;   Drug: Tenofovir Alafenamide;   Other: Knowledge Index Questionnaire;   Other: Liver transient elastography (FibroScan);   Procedure: Liver Biopsy
    Sponsor:   University of Maryland, Baltimore
    Recruiting
  • A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
    NCT03434041
    Condition:   Depressive Disorder, Treatment-Resistant
    Interventions:   Drug: Esketamine 56 mg;   Drug: Esketamine 84 mg;   Drug: Placebo;   Drug: Duloxetine (Oral Antidepressant);   Drug: Escitalopram (Oral Antidepressant);   Drug: Sertraline (Oral Antidepressant);   Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
    NCT04158687
    Condition:   Schizophrenia
    Interventions:   Drug: CTP-692;   Drug: Placebo
    Sponsors:   Concert Pharmaceuticals;   Cognitive Research Corporation
    Recruiting
  • A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
    NCT03669640
    Condition:   Schizophrenia, Schizoaffective Disorder
    Interventions:   Drug: RO6889450;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
    NCT03593213
    Condition:   Schizophrenia
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
    NCT03382639
    Condition:   Schizophrenia
    Interventions:   Drug: TAK-831;   Drug: Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
    NCT04087018
    Condition:   Advanced Solid Tumors
    Intervention:   Drug: AB122
    Sponsors:   Arcus Biosciences, Inc.;   Strata Oncology
    Recruiting
  • Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
    NCT04010305
    Conditions:   Agitation;   Schizophrenia
    Interventions:   Drug: Sublingual film containing BXCL501 (Dexmedetomidine);   Drug: Placebo film
    Sponsors:   BioXcel Therapeutics Inc;   Cognitive Research Corporation
    Recruiting
  • Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
    NCT03738215
    Condition:   Major Depressive Disorder
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • GB001 in Adult Subjects With Moderate to Severe Asthma
    NCT03683576
    Condition:   Asthma
    Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
    Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
    Recruiting
  • A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
    NCT03573297
    Conditions:   Bipolar I Disorder;   Mania;   Depression
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
    NCT02997228
    Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
    NCT02782104
    Condition:   Depressive Disorder, Treatment-Resistant
    Intervention:   Drug: Esketamine Nasal Spray
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
    NCT01805076
    Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
    NCT04109950
    Condition:   Schizophrenia
    Intervention:   Drug: SEP-363856
    Sponsor:   Sunovion
    Recruiting
  • A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
    NCT04072354
    Condition:   Schizophrenia
    Interventions:   Drug: SEP-363856 50mg;   Drug: SEP-363856 75mg;   Drug: Placebo
    Sponsor:   Sunovion
    Recruiting
  • A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
    NCT03893825
    Condition:   Schizophrenia
    Interventions:   Drug: TV-46000;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC